Literature DB >> 14604817

D2s dopamine receptor mediates phospholipase D and antiproliferation.

Susan E Senogles1.   

Abstract

The D2 dopamine receptor, short form (D2s) has been shown to stimulate phospholipase D (PLD) activity independent of activation of phospholipase C (PLC) activity in GH4 derived cells stably transfected with the D2s receptor [Mol. Pharm. 58 (2000) 455]. Agonist activation of D2s has been shown to mediate the inhibition of growth in the same cell line [J. Biol. Chem. 276 (1992) 24169; Endocrinology 134 (1994) 783]. In the present study, D2s-HEK 293 cells were generated using Epstein-Barr virus (EBV) based vectors. The stimulation of PLD by D2s can be augmented by the transfection of Rho A, but not Cdc 42 or Rac and nullified by transfection of N19 Rho A, a dominant negative form of Rho A. Addition of ethanol, at 0.5% reduced the ability of dopamine agonists to inhibit growth in D2s-HEK 293 cells, suggesting that PLD is involved in the antiproliferative effects of D2s signaling. In addition, the expression of N19 Rho A ablated the ability of the D2s to inhibit [3H]thymidine incorporation, while the expression of N19 Cdc 42 or N17 Rac had no effect. These results suggest that the D2s stimulation of PLD is Rho A dependent and lies along the signaling pathway which leads to the antiproliferative effects of D2s receptor activation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14604817     DOI: 10.1016/j.mce.2003.07.001

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  9 in total

1.  Evaluation of D2 and D3 dopamine receptor selective compounds on L-dopa-dependent abnormal involuntary movements in rats.

Authors:  Rakesh Kumar; Lindsay R Riddle; Suzy A Griffin; Wenhua Chu; Suwanna Vangveravong; Janet Neisewander; Robert H Mach; Robert R Luedtke
Journal:  Neuropharmacology       Date:  2009-02-05       Impact factor: 5.250

2.  Comparison of the binding and functional properties of two structurally different D2 dopamine receptor subtype selective compounds.

Authors:  Robert R Luedtke; Yogesh Mishra; Qi Wang; Suzy A Griffin; Cathy Bell-Horner; Michelle Taylor; Suwanna Vangveravong; Glenn H Dillon; Ren-Qi Huang; David E Reichert; Robert H Mach
Journal:  ACS Chem Neurosci       Date:  2012-10-12       Impact factor: 4.418

Review 3.  Single nucleotide polymorphisms as susceptibility, prognostic, and therapeutic markers of nonsmall cell lung cancer.

Authors:  Shanbeh Zienolddiny; Vidar Skaug
Journal:  Lung Cancer (Auckl)       Date:  2011-12-29

4.  Evaluation of the D3 dopamine receptor selective agonist/partial agonist PG01042 on L-dopa dependent animal involuntary movements in rats.

Authors:  Lindsay R Riddle; Rakesh Kumar; Suzy A Griffin; Peter Grundt; Amy Hauck Newman; Robert R Luedtke
Journal:  Neuropharmacology       Date:  2010-09-17       Impact factor: 5.250

Review 5.  Dopamine and G protein-coupled receptor kinase 4 in the kidney: role in blood pressure regulation.

Authors:  Pedro A Jose; Patricio Soares-da-Silva; Gilbert M Eisner; Robin A Felder
Journal:  Biochim Biophys Acta       Date:  2010-02-12

Review 6.  Resistant prolactinomas.

Authors:  V Vasilev; A F Daly; L Vroonen; S Zacharieva; A Beckers
Journal:  J Endocrinol Invest       Date:  2011-03-15       Impact factor: 4.256

7.  α-Synuclein expression in rat substantia nigra suppresses phospholipase D2 toxicity and nigral neurodegeneration.

Authors:  Oleg S Gorbatyuk; Shoudong Li; Frederic Nha Nguyen; Fredric P Manfredsson; Galina Kondrikova; Layla F Sullivan; Craig Meyers; Weijun Chen; Ronald J Mandel; Nicholas Muzyczka
Journal:  Mol Ther       Date:  2010-07-27       Impact factor: 11.454

8.  Dopamine D3 receptor selective ligands with varying intrinsic efficacies at adenylyl cyclase inhibition and mitogenic signaling pathways.

Authors:  Michelle Taylor; Peter Grundt; Suzy A Griffin; Amy Hauck Newman; Robert R Luedtke
Journal:  Synapse       Date:  2010-03       Impact factor: 2.562

Review 9.  Lipid Rafts and Dopamine Receptor Signaling.

Authors:  Victor J Martinez; Laureano D Asico; Pedro A Jose; Andrew C Tiu
Journal:  Int J Mol Sci       Date:  2020-11-24       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.